Sujal Shah - Dec 11, 2023 Form 4 Insider Report for CymaBay Therapeutics, Inc. (CBAY)

Role
Chief Executive Officer, Director
Signature
/s/ Paul Quinlan, as attorney-in-fact for Sujal Shah
Stock symbol
CBAY
Transactions as of
Dec 11, 2023
Transactions value $
-$972,845
Form type
4
Date filed
12/11/2023, 07:03 PM
Previous filing
Nov 14, 2023
Next filing
Jan 26, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CBAY Common Stock Options Exercise $320K +64K +37.35% $5.00 235K Dec 11, 2023 Direct
transaction CBAY Common Stock Sale -$1.28M -64K -27.19% $19.99 171K Dec 11, 2023 Direct F1, F2
transaction CBAY Common Stock Options Exercise $4.45K +890 +0.52% $5.00 172K Dec 11, 2023 Direct
transaction CBAY Common Stock Sale -$18.5K -890 -0.52% $20.81 171K Dec 11, 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CBAY Employee Stock Option (right to buy) Options Exercise $0 -31K -100% $0.00* 0 Dec 11, 2023 Common Stock 31K $5.00 Direct F3
transaction CBAY Stock Appreciation Right Options Exercise $0 -13K -100% $0.00* 0 Dec 11, 2023 Common Stock 13K $5.00 Direct F4
transaction CBAY Employee Stock Option (right to buy) Options Exercise $0 -20.9K -100% $0.00* 0 Dec 11, 2023 Common Stock 20.9K $5.00 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into on June 28, 2023.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.78 to $20.56, inclusive. The reporting person undertakes to provide to CymaBay Therapeutics, Inc., any security holder of CymaBay Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 The option vested over a four-year period, with one-third of the shares subject to the option vesting on the grant date of December 23, 2013, and the remaining 2/3 of the shares subject to the option vesting ratably on a monthly basis over the 48 months thereafter.
F4 The award was granted under the CymaBay 2013 Equity Incentive Plan and can be settled in cash or shares of CymaBay common stock, at the sole discretion of CymaBay. The award vested in full on the two-year anniversary of the grant date.
F5 The option vested over a four-year period, with one-third of the shares subject to the Option vesting on the grant date of January 6, 2014, and the remaining 2/3 of the shares subject to the Option vesting ratably on a monthly basis over the 48 months.